These Form 3 filings confirm the appointment of a CFO and COO, likely part of a post-merger management structure following the Orphai Therapeutics merger. Monitor upcoming Form 4 filings for any open-market purchases or sales by these insiders for signals on conviction.
Price Chart
Executive Summary
Two Form 3 filings were submitted for IRulya Therapeutics Inc. by new officers John Militello (CFO) and Keith R. Fandrick (COO), each accompanied by a power of attorney authorizing others to file Section 16 reports. Fandrick's filing discloses stock options received in exchange for prior Orphai Therapeutics options pursuant to a May 2026 merger agreement, including options to acquire 92,168 shares at $16.81 and numerous smaller grants at ~$1.81. These are routine initial ownership reports for newly appointed officers and do not contain material financial information or trading activity.
Key Facts
- John Militello appointed as Chief Financial Officer and filed Form 3 on 2026-10-19 (period of report 2026-10-08).
- Keith R. Fandrick appointed as Chief Operating Officer and filed Form 3 on 2026-10-19 (period of report 2026-10-08).
- Fandrick's Form 3 discloses employee stock options to buy common stock at exercise prices ranging from $1.80 to $16.81, with expiration dates from 2027 to 2036.
- Fandrick's options were received in exchange for prior Orphai Therapeutics options under an Agreement and Plan of Merger dated May 17, 2026.
- Both filings include a Power of Attorney authorizing Brigette Roberts (and for Fandrick also John Militello) to execute Section 16 filings on their behalf.
- No actual shares of common stock are reported as directly owned by either reporting person.
- Fandrick's largest disclosed option is for 92,168 shares at $16.81 per share, expiring 2036-05-11.
Financial Impact
No financial impact — these are initial beneficial ownership statements with no trading or capital event.
Risk Factors
- No trading activity disclosed — no immediate risk signal.
- Post-merger integration execution risk is present but not quantified in these filings.
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (IRLA) — Batch item 1 | 0001662170-26-000002 |
| Document: 0001662170-26-000002-index-headers.html | 0002159394-26-000002 |
| Document: 0001662170-26-000002-index.html | 0001662170-26-000002 |
| Document: 0001662170-26-000002.txt | 0001662170-26-000002 |
| 3 Filing (IRLA) — Batch item 5 | 0002159394-26-000002 |
| Document: 0002159394-26-000002-index-headers.html | 0001662170-26-000002 |
| Document: 0002159394-26-000002-index.html | 0001662170-26-000002 |
| Document: 0002159394-26-000002.txt | 0001662170-26-000002 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 144 | $32.83 | awaiting T+20 | — | $33.08 (+0.76%) |
Oct 19, 2026 7d ago | 3 | $40.27 | awaiting T+20 | — | $33.08 (−17.85%) |
Oct 19, 2026 7d ago | 3 | $40.27 | awaiting T+20 | — | $33.08 (−17.85%) |
Oct 19, 2026 7d ago | 3 | $40.27 | awaiting T+20 | — | $33.08 (−17.85%) |
Oct 19, 2026 7d ago | 3 | $40.27 | awaiting T+20 | — | $33.08 (−17.85%) |
Oct 19, 2026 7d ago | 3 | $40.27 | awaiting T+20 | — | $33.08 (−17.85%) |
Oct 19, 2026 7d ago | 8-K | $34.45 | awaiting T+20 | — | $33.08 (−3.98%) |
Oct 14, 2026 12d ago | SC 13G | $33.23 | awaiting T+20 | — | $33.08 (−0.45%) |
Oct 14, 2026 12d ago | SC 13G | $33.23 | awaiting T+20 | — | $33.08 (−0.45%) |
Oct 6, 2026 20d ago | 8-K | $26.72 | awaiting T+20 | — | $33.08 (+23.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers